News

Article

Diurnal’s Swiss Partner Submits MAA for Alkindi to Swissmedic

The Swiss marketing and distribution partner of Diurnal Group, EffRx Pharmaceuticals, has submitted a MAA for Alkindi to Swissmedic.

The Swiss marketing and distribution partner of Diurnal Group, EffRx Pharmaceuticals, has submitted a marketing authorization application (MAA) for Alkindi to the Swiss regulatory body, Swissmedic.Alkindi

According to an Oct. 21, 2020 press release, the MAA has been based on the European regulatory dossier and published clinical trial data on Alkindi—hydrocortisone granules in capsules for opening. EffRx anticipates a potential market launch for Alkindi in Switzerland by 2022 and will receive the exclusive rights to market and sell the product in Switzerland once the product has been registered.

“We are pleased to see the submission of a MAA for Alkindi in Switzerland by EffRx,” said Martin Whitaker, CEO of Diurnal, in the press release. “[This] announcement is yet further validation of the quality of our products and broadens the future availability of Alkindi outside our core markets in line with our global strategy. We look forward to working with EffRx to make Alkindi available to patients suffering from pediatric adrenal insufficiency (AI) in Switzerland.”

Alkindi is already approved and marketed in Europe and is the first preparation of hydrocortisone that has been specifically designed for pediatric use in the treatment of AI and the related condition, congenital adrenal hyperplasia.

Source: Diurnal

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content